

Action for Pulmonary Fibrosis

Annual Report and Accounts

1 July 2024 – 30 June 2025

Charity Commission England & Wales Registered Charity Number: 1152399
Scottish Charity Regulator Number: SC050992

actionpf.org

Contents

150,000+
people are currently living with pulmonary fibrosis

18,000
new cases of pulmonary fibrosis diagnosed each year

5,000+
people die from idiopathic pulmonary fibrosis (IPF) each year

Our Impact in 24-25

£2million
raised to support people and families with PF

Publications

4,587
About APF leaflet sent out to people

3,280
Understanding PF leaflet sent out to people

7,233
pirfenidone and nintedanib leaflets ordered

Digital

1,000+
people registered for our new education webinars

326,000
online views of our information resources

22,500+
website visitors per month

Support

3,000+
support line interactions

87
signposts to regional support groups across the UK

Research

£600,000
committed to advancing new research

19
studies added to our research study finder

160
people in our involvement network, now double the size

Welcome

Every day, people affected by pulmonary fibrosis turn to Action for Pulmonary Fibrosis for clarity, reassurance and support.

Over the past year, we responded to that need with greater reach, depth and consistency than ever before. More people contacted us for help, more families accessed trusted information, and more communities were supported to connect, share experience and feel less alone. At the same time, we strengthened the foundations needed to deliver high-quality support across the UK and to drive progress in research, now and in the years ahead.

Demand for support continued to grow as many people experienced delays in diagnosis, uneven access to specialist care and inconsistent information. In response, we expanded capacity across our services, strengthened professional expertise and widened access to reliable, accessible resources. From one-to-one conversations at moments of uncertainty, to education, peer support, research participation and national advocacy, our work focused on meeting people where they are and responding to what they need most.

Through the generosity of our supporters, APF received nearly £2 million in funding, the largest amount in our history. This enabled us to support people living with pulmonary fibrosis today, while also investing in high-quality research, systems change and partnerships that will improve understanding, treatment and care for future generations.

Above all, we thank the pulmonary fibrosis community. The experiences, insight and determination of people living with PF, and of those who care for them, shape every aspect of our work. Lived experience remains central to how we deliver services, influence policy and design and fund research, ensuring that progress is driven by real needs and real lives.

The sections that follow set out how this support and progress were delivered in practice over the year, from frontline services and peer support, to research, policy influence and national awareness. Together, they reflect both the impact achieved now and the foundations being laid so that no one affected by pulmonary fibrosis is left without information, support or a voice.

Daniel Saxton
Chief Executive Officer

Mike Stubbins
Chair

In memory of Clare Hodkinson

It is with great sadness that we remember **Clare Hodkinson**, a much-valued member of the Action for Pulmonary Fibrosis research team, who passed away during the year while in service.

Clare was living with pulmonary fibrosis and played a key role in establishing APF's grant-giving programme, helping to support researchers across the UK to advance understanding, care and treatment of pulmonary fibrosis. She brought to her work exceptional professionalism, insight and generosity of spirit, and her contribution continues to shape our research activity.

Clare is deeply missed by colleagues, partners and the pulmonary fibrosis community she cared so deeply about.

Who we are

Action for Pulmonary Fibrosis (APF) is the UK’s leading charity dedicated to supporting people affected by pulmonary fibrosis (PF), driving research and shaping policy. We are rooted in the lived experiences of patients, families, carers and clinicians and united by a shared belief that **people with pulmonary fibrosis deserve better**.

Our work spans four interconnected areas:

Support	Awareness	Advocacy	Research
Providing trusted, compassionate support for people affected by pulmonary fibrosis.	Raising the profile of pulmonary fibrosis and tackling stigma and misinformation.	Campaigning for faster diagnosis, better care, and health equality.	Funding and influencing science that improves lives and brings hope.

Thanks to the generosity of our donors, funders, volunteers and partners, APF is able to reach more people impacted by pulmonary fibrosis every year, offering hope, support and a platform for raising awareness of this life-limiting condition.

Why APF is needed

Since our founding in 2013, Action for Pulmonary Fibrosis has grown from a grassroots initiative into the UK's leading charity for people affected by pulmonary fibrosis and a world-leading voice in pulmonary fibrosis patient advocacy. Born from the vision of patients and clinicians who knew that people deserved better, APF has become a driving force for support, awareness, research and policy change.

Support

We recognise the significant gap in both awareness and support for those affected by pulmonary fibrosis. Due to limited knowledge about the condition and the lengthy process of diagnosis, many individuals and families face uncertainty and isolation at a time when timely support is crucial. In healthcare settings, the support offered is often minimal, leaving patients and caregivers without the resources and guidance they need.

We offer a compassionate **support line** that offers personalised support for individuals and families navigating the challenges of the condition. Alongside this we offer a wide range of **information resources**, both digitally and in hard copy, to help people better understand the disease, its progression and available treatments. Through our **educational webinars**, we equip patients, caregivers and healthcare professionals with the latest knowledge to manage pulmonary fibrosis effectively. Additionally, we support a growing network of **local support groups**, fostering a sense of community and offer a **befriending service** that connects individuals with others who have lived experience, helping to reduce isolation and provide emotional support.

Awareness

Pulmonary fibrosis is a devastating disease and for far too long, it has been under-recognised, underfunded and misunderstood.

It causes progressive scarring of the lungs, making them stiff and reducing their ability to take in oxygen. This leads to breathlessness, a persistent cough and debilitating fatigue, making even simple tasks like getting dressed or walking short distances exhausting.

In the UK, it is estimated that **over 150,000 people are currently living with pulmonary fibrosis**, around **18,000 new cases are diagnosed**[1] **each year** in England alone and **more than 5,000 people die from the idiopathic pulmonary fibrosis (IPF) alone each year**.[2] Treatment options are limited, and there is no known cure.

Alarmingly, **one in three people in the UK have never heard of pulmonary fibrosis**. Without awareness of the symptoms, many individuals miss the chance to seek help early.

By raising awareness, we can ensure people get the support and medical care they need as soon as possible.

---

[1] Extrapolation based on Gupta R, Morgan AD, George PM, et al Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in England from 2008 to 2018: a cohort study Thorax 2024;79:624-631.

[2] BTS ILD Registry Annual Report 2021, available at: https://www.brit-thoracic.org.uk/document-library/quality-improvement/ild-registry/uk-ipf-registry-2021-summary-for-the-general-public/

Why APF is needed

Advocacy

Although pulmonary fibrosis can progress rapidly, access to specialist care and accurate information is still inconsistent across the UK. These delays not only leave people feeling abandoned, but they can also allow the disease to advance, reducing the effectiveness of any future treatment.

Every year, more people turn to APF with advancing symptoms and increasingly complex healthcare needs. As the disease progresses, it places a growing physical, emotional and financial burden on both patients and their loved ones. This underlines the urgent need for earlier diagnosis, intervention and consistent, high-quality support.

Research

Despite its severe impact, pulmonary fibrosis remains drastically underfunded, with respiratory research receiving just 2% of the UK's total medical research funding. This lack of investment is a major barrier to finding new treatments and ultimately, a cure.

We believe no one should have to face pulmonary fibrosis alone. By expanding our support, partnering with healthcare professionals and driving forward research, we aim to end the fear, isolation and the loss of life caused by this disease.

Together, we can shine a light on this overlooked condition and offer real hope to those affected.

Our purpose, vision and mission

Our purpose

We bring people together to drive change so that everyone affected by pulmonary fibrosis can live well for longer.

Our mission

We work together to stop lives being lost to pulmonary fibrosis.

Our vision

A future where everyone with pulmonary fibrosis has access to effective, evidence-based care and ultimately, a cure.

We are a values-led organisation. In everything we do, we strive to be:

Compassionate

Listening to and acting on the voices of people affected by pulmonary fibrosis.

Bold

Challenging inequality and pushing for lasting change.

Expert

Combining lived experience with scientific and clinical evidence to inform everything we do.

Collaborative

Working across sectors and communities to achieve greater impact together.

The difference we make

Action for Pulmonary Fibrosis (APF) are committed to making a meaningful difference for everyone affected by pulmonary fibrosis (PF) by bringing hope and lasting support.

Through our dedicated Support Line, we provide a vital service, offering guidance, resources and emotional support to individuals and their families. In addition to our print and digital resources, we offer learning and empowerment through educational initiatives, including webinars and support groups.

We also advocate for critical research, policy changes and increased awareness to improve care and outcomes for those impacted by the condition. Our fundraising and communication efforts are essential in engaging the community, raising awareness and generating the support needed to drive these initiatives forward.

Over the last year we've reached more people than ever, deepened our impact and strengthened our community so no one has to face pulmonary fibrosis alone.

The difference we make

Support in action

Support Line

Our Support Line offers information, guidance and a listening ear to anyone affected by pulmonary fibrosis. Our trained team, managed by a specialist nurse, provide expert support and reassurance from practical information, emotional support or simply someone to talk to.

We answered over **2,000 calls** to our Support Line, a **31% increase** on the previous year.

Across the year, we saw the total number of contacts to our Support Line rise to **over 3,000**, a **38% increase** on the previous year.

> I am extremely grateful for the support, information and patience given to me. The Support Line offers hope at a time of great difficulty.
>
> **Patient living with pulmonary fibrosis**

> I can’t begin to express how grateful my family and I are for the incredible support we’ve received from APF’s specialist nurse on the Support Line. At a time when my father’s pulmonary fibrosis diagnosis left us feeling overwhelmed and uncertain, they stepped in with not only vast medical knowledge but also with compassion and kindness. They have been a beacon of clarity and comfort. We are forever grateful.
>
> **Family member of person living with pulmonary fibrosis**

These personal stories emphasise the profound impact that timely support can have, particularly given the complex and fast-progressing nature of pulmonary fibrosis. Delays in receiving clinical care often lead people to contact us when their symptoms have advanced, making our support line an essential resource for many people, including their families and loved ones.

The difference we make

Support in action

Information and education

We understand that navigating a health condition can be overwhelming, which is why providing accessible, reliable and up-to-date information is at the heart of what we do. Through a combination of printed, digital resources and our expanding educational offerings, we strive to ensure that individuals and families have the support they need, when they need it.

We produced a new **Carers Booklet** of which 377 copies were downloaded, and 1,394 printed copies were ordered.

Our **About APF leaflet** was ordered and sent out 4,587 times and **Understanding PF**, 3,280 times.

Our **Recently Diagnosed pack** was sent out to 1,339 people whilst our **Benefits leaflet** was ordered 1,783 times.

Our most popular resources continue to be our leaflets on the antifibrotics treatments: **pirfenidone** and **nintedanib** which were ordered 7,233 inclusively.

Throughout the year our resources are reviewed and updated and we are progressing further information resources on worsening symptoms, difference between ILD and PF, eating well, end of life, grief and bereavement and oxygen.

We are also continuing to reflect our commitment to inclusivity by launching additional **translated resources**:

- The popular Recently Diagnosed pack is now available in Urdu and Welsh
- The treatment information resource Antifibrotics launched in Polish and Welsh

Our **online information resources**, accessible on the APF website, include symptom guides, treatment options and expert advice, have had over **326,000 views**. The most common page visit was ‘cough’ which had over **30,000 views**.

In October 2024, we launched a new programme of education webinars. Feedback following all the webinars highlighted an average rating of 4.5/5 with over 1,000 people registering to attend throughout the year.

Navigating **PF**
Webinar series

Talking **PF**
Webinar series

> Very clear and well presented, without overloading the listener but providing a lot of information. I am so pleased I signed up to listen to it.
>
> **Anonymous website feedback form**

> The session was positive and helpful with clear information presented. Thank you.
>
> **Anonymous website feedback form**

The difference we make

Support in action

Support groups and professionals

We are proud to support healthcare professionals (HCPs), patients, carers and bereaved carers to set up and run independent support groups in their local communities. Alongside managing and facilitating our own groups, we work closely with the local support group leaders to help them create welcoming spaces where people can connect and share experiences. These groups form a vital focus of peer-to-peer support, reducing isolation and helping people affected by pulmonary fibrosis feel less alone.

> Thanks for supporting our first patient get together. It was a wonderful surprise to see so many people given the time of year and cold weather. Having Action for Pulmonary Fibrosis there to support was amazing and I hope they can support us at future events.
>
> **Jane Cowell, Respiratory Nurse, Gloucestershire Royal Hospital**

Local support groups

- Increased the number of support groups we signpost to through our website from 66 to 87 across the UK.
- Directly engaged with 2,142 support group members during 114 visits.
- Awarded 11 support group grants, to help new groups set up, with a total value of £4,875.

APF support groups

- These specialist groups were originally set up for support groups leaders, carers and anyone who has had, or is on, the transplant waiting list.
- This year we launched three new specialist groups for bereaved carers (life after caring), a Scottish rural network and a group for working age and younger people
- We facilitated 36 APF support group meetings during the year, attended by 597 people.

Healthcare professionals

- We network with HCPs to help establish new support groups in geographical areas where there are none.
- We have directly engaged with 1,312 HCPs at national conferences, regional respiratory and voluntary sector events.
- We have attended 55 clinic sessions in six UK hospitals, raising awareness of APF with nearly 1,000 people.

> Since I joined the group, I felt there was an understanding and friendship which wrapped me in a blanket of support.
>
> **Member of carers group**

The difference we make

Advancing research and participation

In the past year, our commitment to advancing research has continued to define our work. APF remains dedicated to being the catalyst for groundbreaking research into pulmonary fibrosis.

Direct Funding

In 2023–24, we committed **£600,000** to **advancing new research** through the funding of two, three-year fellowships. These continue to go from strength to strength, with notable progress from Dr Jenny Dickens, a Mike Bray Fellow at the University of Cambridge, who has recently been appointed Principal Investigator at the Cambridge Institute for Medical Research.

> We know that the only way to make a change in pulmonary fibrosis is via bold research. It's only through supporting innovative research like these projects that we can discover insights which will drive improvements for the lives of people with pulmonary fibrosis.
>
> **Bradley Price, Director of Policy, Research and Involvement**

The difference we make

Advancing research and participation

Small Research Grants

Our newly launched Small Research Grant Programme has allocated £20,000 to support UK-based researchers in advancing evidence to improve care and treatment. The programme has funded projects focused on analysing existing data to identify trends and inform policy, capturing patient and caregiver experiences through qualitative research and conducting scoping reviews to highlight knowledge gaps and shape future research priorities.

The two successful projects look at:

- Understanding the pathway to diagnosis and treatment of pulmonary fibrosis in the UK. It will look at the clinical experience of people with pulmonary fibrosis as they move through the healthcare system. This will help to identify where delays are occurring and who is more likely to experience such delays.
- The burden of sleep disordered breathing in progressive pulmonary fibrosis using retrospective data. This will help to identify health disparities across different groups and identify barriers and solutions.

> I feel privileged to be one of two recipients of APF's Small Research Grants. This grant will fund research into patient pathways – a detailed look at patients' journeys through the UK health-care system with a view to identifying barriers to earlier diagnosis. I am looking forward to beginning my research journey with support from APF and I hope that longer term, my work will help deliver diagnostic and treatment services for pulmonary fibrosis that are on a par with those for we currently have for cancer.
>
> **Dr Ann Morgan, Small Research Grant recipient**

The difference we make

Advancing research and participation

Early-career support

We funded Conference Awards to **seven early-career researchers**, enabling them to present cutting edge pulmonary fibrosis research at national and international conferences.

Alongside this we collaborated with the British Association of Lung Research (BALR) to fund a further two summer internships. Two students from University College London and the University of Birmingham will undertake an 8-week summer research project alongside senior interstitial lung disease researchers. One project looks at the behaviour of immune cells in idiopathic pulmonary fibrosis (IPF), whilst the other is using a 3D lung model to investigate the effects of a protein blocker on IPF.

Study Finder

After the successful launch of our **Study Finde**r in 2024, we have added a further 19 studies in accessible language, to help people who may want to take part in research, to understand what is currently happening and how they could take part. This tool had over 5,000 views, demonstrating the interest in taking part in research.



Take part in research

Find a research study

Ask your healthcare team about taking part in research

Explore the Study Finder to learn about research that is happening in the UK today. You may be able to take part.

Need help? Take a look at our information guide.

Are you a researcher currently recruiting participants in the UK? If you would like your study included on this page, please complete this online form.

20 result/s

Can Buloxibutid help people with IPF?
Recruiting · 1 year participation
ASPIRE
Sponsored by: Vicore Pharma

SENTINEL study: Can a skin flap in lung transplant identify organ rejection earlier?
Recruiting · 1 year participation

Can antibody testing help to identify risk for vulnerability to COVID-19?
Recruiting · Until Spring 2025 participation
Stravinsky

How is mental health and wellbeing impacted for people with IPF living in Ireland?
Recruiting · 20 minutes participation

European IPF Registry and Biobank

Involvement Network

The Involvement Network is a group of people who have lived experience of pulmonary fibrosis. We work closely with them to gain valuable insights and feedback on all aspects of our work and ensure that their challenges and perspectives are considered and integrated into what we do. This collaboration helps us create more compassionate and inclusive services, making sure that those directly impacted by pulmonary fibrosis are at the heart of what we do. We have:

- Doubled the number of people who are part of our involvement network to 160.
- Worked to recruit a diverse audience to ensure involvement activities accurately represent the breadth of the pulmonary fibrosis community.
- Provided Patient and Public Involvement (PPI) support to the CHORUS trial, a £2 million study funded by the National Institute for Health Research (NIHR) which looks at whether prednisolone helps slow down lung damage in people recently diagnosed with fibrotic hypersensitivity pneumonitis (a form of PF).
- Driven engagement with academia and industry to ensure patient views and preferences are represented across all types of research:
    - Supported PPI on 15 external projects
    - Ensured our Mike Bray Fellows have strong involvement from the patient community across their research.

Influencing and policy

Our Policy and Public Affairs team has continued to drive change that will transform the lives of people with pulmonary fibrosis. We have strengthened our advocacy program, influenced national policy discussions and ensured a wider awareness of pulmonary fibrosis in government and the NHS. Together, we are reshaping the future of pulmonary fibrosis care and creating lasting change.

OneVoiceILD and the National Integrated Care Pathway

In April 2024, APF spearheaded the launch of the OneVoiceILD national integrated care pathway, a blueprint to end the postcode lottery for pulmonary fibrosis diagnosis, care, treatment and support. This year has seen several pilot projects underway in England, looking to understand the different ways in which the pathway can be used and how they can overcome the challenges associated with implementation.

Devolved nations – developing pathways

- Agreed a consensus pathway for Northern Ireland, looking to standardise care and set a clear timed pathway for suspected ILD diagnosis and treatment.
- Worked with NHS Wales Performance and Improvement to design a new timed pathway for Wales.
- Worked with the Centre for Sustainable Delivery to design a new pathway for Scotland.

Supporting change

- Developed a business case tool kit: a practical guide to writing an impactful business case to boost local ILD services. This aims to address some of the challenges relating to waiting times and unequal access to services, in line with our goal of bringing ILD care closer to home.
- Delivered a presentation at the British Thoracic Society Winter Meeting, showcasing how the patient voice shapes clinical pathways and drives systems change.

Lived Experience

- The OneVoiceILD Lived Experience Panel, made up of patients and carers, offers invaluable firsthand insights to ensure our NHS transformation and pathway development align with real-world needs.

Influencing and policy

Parliamentary engagement

Through stronger engagement with parliamentarians, we're amplifying the voice of the pulmonary fibrosis community in key policy conversations. This growing momentum is vital to our mission of securing fair, compassionate and effective care for everyone affected by pulmonary fibrosis across the UK.

- We held an event focused on raising awareness of the links between social deprivation, distance from respiratory clinic and the outcomes in pulmonary fibrosis.
- Supporters were encouraged to email their MP and ask them to attend our parliamentary event.
- Over 1,100 emails were sent and over 40 MPs attended the event (almost 100% increase on the previous year).
- Arranged an Early Day Motion (EDM) in the House of Commons which was signed by 40 MPs. The EDM: "welcomes the ILD Care Pathway developed by OneVoiceILD, supported by Action for Pulmonary Fibrosis".

Co-hosted a Roundtable in the Scottish Parliament on Interstitial Lung Disease. Held to both raise awareness of the impact of the various conditions that sit under the umbrella of Interstitial Lung Disease (ILD) and to share the experiences and hopes of patients and clinicians for better ILD diagnosis and care in Scotland.

Understanding the reality of pulmonary fibrosis

Following on from the success of the 'I Wish It Was Cancer' report, this year saw the development of the 'State of the Nation' survey. The survey is aiming to create a quantitative dataset from people affected by pulmonary fibrosis which can be used to shape APF's work and provide robust information to help influence healthcare systems. We specifically want to understand the issues faced as a result of existing pathways and where the key areas of improvement are.

To help inform the questions of the survey and understand what is causing issues for people living with pulmonary fibrosis, we held 6 sessions, with each concentrating on a different group, such as people with different types of pulmonary fibrosis and carers.

Driving the policy conversation

This year we responded to national consultations on the NHS 10 Year Plan and the Darzi Review, highlighting key priorities for change. We also represented the views of people with pulmonary fibrosis in the NICE appraisal of a treatment for pulmonary hypertension associated with ILD (PH-ILD).

Shining a light on pulmonary fibrosis

Raising awareness of pulmonary fibrosis is at the heart of our mission. Despite its profound impact, many people have never heard of the condition, making education, visibility and public engagement essential. Through media coverage, powerful campaigns and clear, accessible resources, we strive to educate the public, spark important conversations and ultimately encourage earlier diagnoses and improved outcomes. By sharing personal stories and showcasing the latest research, we work to ensure that pulmonary fibrosis is no longer an unseen condition.

Growing reach

- **22,500+** average **website visitors** per month, with the majority of users coming organically from a search engine, strongly followed by a direct search of APF.
- **6,800+ e-newsletter subscribers** showing a 32% increase on last year and with an average open rate of over 47%.
- **23,500+ social media followers** with an increase of 12%, an additional 2,555 followers in the year.

We continue to see the number of subscribers to our **Insider magazine** grow. The publication is distributed twice a year in print and digital format:

• Spring/Summer 2024	4,319 subscribers
• Autumn/Winter 2024	4,671 subscribers
• Spring/Summer 2025	5,462 subscribers

When asked the following question: 'How likely are you to recommend Insider to other people with pulmonary fibrosis', feedback from 17 reviews were submitted

- 15/17 'very likely'
- 1/17 'unsure'
- 1/17 'very unlikely'.

Insider

Living well with pulmonary fibrosis

Action for Pulmonary Fibrosis

Autumn/Winter 2025

Hope for the future: current research

'It's one big learning curve' – Sarah's story

Celebrating incredible support groups

Benefits information made simple

actionpf.org

Evidence for change

We know that pulmonary fibrosis (PF) care needs to change, but we have to prove it. Change doesn't happen without evidence, and that's the purpose of our 2025 State of the Nation survey. It shows what needs to change and why it can't wait. We're putting all this evidence into a report that could shape the future of PF care.

What is the State of the Nation Survey?

In June 2025, we launched the State of the Nation survey to learn about people's experiences with PF health services. We asked about:

- Where you first reported your symptoms.
- If you were misdiagnosed.
- How long it took until you received a diagnosis.

> "The response to the survey was incredible – more than 1,200 people took part. Thank you to everyone who took the time to complete the survey. Every response matters."
>
> **Lisa Murray, Policy & Public Affairs Officer**

By understanding what's working, and what isn't, we can start to work on changing things for the better. This survey builds on our 2023 survey, which explored the individual impact of being affected by PF. You can read the results of the 2023 survey in our I Wish It Was Cancer report.

Read the I Wish It Was Cancer 2023 report here

bit.ly/surveyreport2023

What will the survey do?

Every answer helps to build a picture of PF care. This helps to prove that these issues are real, and many people are affected by them. We've worked with expert analysts to dig deeper into the responses and find patterns that might go unnoticed. For example, we're asking:

- Are people more likely to be misdiagnosed if they seek help from A&E than their GP?
- Do people with a certain type of PF wait longer to be referred to a specialist?

Your experiences become powerful evidence. They help us to understand how people affected by PF navigate the healthcare system. These insights help NHS decision-makers and clinical teams to make better-informed decisions about PF care. These decisions could directly improve someone's journey through diagnosis, treatment and ongoing care.

What happens next?

Once this analysis is complete, we'll publish a full report that sets out the key insights. This will give us the facts and figures we need to back up what we often hear – that things need to change. We'll use this evidence to guide our work with NHS decision-makers and clinical teams across the UK. We will:

- Show where services aren't working well, so no one misses out on the care and support they need.
- Start informed discussions with those in charge about what needs to change.
- Support clinicians and service planners who want to improve ILD services across their region.

A vital piece of the puzzle

Peter, aged 71 from Devon, cared for his wife who had PF. He helped to decide what should be in this year's survey to ensure we truly understand the experiences of people affected by PF.

'Decision makers need more than stories,' Peter explains. **'They also need evidence – hard numbers - before they will act. It's tough to win support for PF in today's world, with so many other causes competing for attention. Surveys like this give funders and politicians proof they can't ignore – whether it's the 'soft' evidence of personal stories, or the 'hard' facts.'**

> "Being a part of the group that helped design the survey made me feel like I am contributing something. Maybe small, but hopefully it's a valuable piece of the puzzle."
>
> **Peter, living with PF**

Whether you share your experiences, shape research, or take part in campaigns, you're helping to shape our work.

Find out more about the APF Involvement Network.

involvement@actionpf.org

01733 839642

How can I read the report when it's published?

Sign up to our e-newsletter and you'll be notified when we publish the report.

bit.ly/apf-news

8 Insider | Autumn/Winter 2025

Insider | Autumn/Winter 2025 9

Influencing and policy

PF Awareness Month

Every September APF launches a campaign to coincide with Pulmonary Fibrosis Awareness Month, a global opportunity to increase visibility, educate, inspire action and drive positive change. Awareness month brings people together to unite around a common goal, offers a platform to get involved with fundraising and ultimately, raise awareness of the severity, symptoms and impact of living with pulmonary fibrosis.

- PF Month 2024 delivered a hard-hitting video, ‘Breathe’, designed to highlight the symptom of breathlessness to the wider audience, which was met with an overwhelmingly positive response.
- A mix of organic and paid-for social media posts reached over 103,000 people with hundreds of comments of support.
- 101 media articles mentioned APF with an estimated reach of 196 million. This was boosted by an APF presence across multiple BBC outlets, feeding into local media.

> Really impactful campaign – keep up the amazing work APF. Your support and dedication to raising awareness of the dreadful disease is inspiring.
>
> **Social media comment**

> Incredible piece of work representing what we go through.
>
> **Social media comment**



Influencing and policy

Case study

Fiona was diagnosed with pulmonary fibrosis at 37. Since then, she's become a mum to her son, Harry and shared her story as part of our Pulmonary Fibrosis Month 2024 campaign with an exclusive piece with the Press Association. Her story reached a national and regional audience in December 2024, resulting in a total reach of approximately 1.6 billion. Significant coverage appeared in publications such as The Mirror, Surrey Live and Manchester Evening News.

In June, Fiona was a guest on The Apple & The Tree podcast with her dad, Steven, where they talked openly about the impact of pulmonary fibrosis on their family. Fiona also reflected on how much our Support Line helped her during a difficult time

This high-profile case study highlights the power of personal stories in raising awareness and driving media engagement.

Our fundraising achievements and supporters

2024-2025 has been an exceptional year for APF, and we owe this success to the **unwavering support of our incredible community** and the **dedicated fundraisers** who have gone above and beyond in their efforts. Thanks to their hard work and generosity, we have raised nearly **£2 million**, an astonishing achievement.

These efforts allow us to continue providing vital services and care, while also driving forward research that holds the potential for ground-breaking advancements in treatment. With every donation, every event and every individual who gets involved, we are one step closer to a world where no one has to face pulmonary fibrosis alone.

Legacies and in memory giving

We are always so touched by anyone who chooses to support us through donations following funerals or as a way of remembering loved ones. 100’s of dedication pages were set up over the year and over £385,000 was raised.

Alongside this we have received nearly £450,000 from gifts in Wills, including a significant gift of over £250,000 from one legator. We are forever grateful that people choose to remember APF in this way. A legacy gift is an incredibly meaningful contribution that has a lasting impact and provides us with the ability to plan for the future with confidence.

> I hope the funds raised go wherever they’re needed most to support patients and carers. The APF community has been a lifeline for me.
>
> **Graham Daubney, community fundraiser**

Challenge and community events

Challenge and community events continued to be very popular throughout the year with some exceptional fundraisers going above and beyond. So many people got involved in so many activities, from the Three Peaks to the Great Manchester Run, from the Glasgow Kiltwalk to the London Marathon.

We also saw incredible fundraising in peoples communities, from golf days to music concerts, from rugby tours to support groups activities. There are always too many supporters to mention, but we thank each and every one that helped to raise over £480,000, an incredible contribution.

> It has been a labour of love for my dad, and a huge comfort to know that Action for Pulmonary Fibrosis is making such a powerful difference to sufferers and their families. It’s been an honour to collaborate with Andy.
>
> **Sarah Rolph, community fundraiser and professional singer who organised a concert called ‘Breathe’**

Our fundraising achievements and supporters

Case study

Sian and her dad, Colin, organised a Yorkshire Three Peaks trek in memory of their mother and wife, Emma and raised an incredible £16,000 for APF. Sian shares her story:

"After my mum passed away, I decided to take on The Three Peak Challenge, a goal I discussed with her when she was with us. Since we shared our plans, many have generously offered to participate in raising both funds and awareness for Action for Pulmonary Fibrosis.

Mum was diagnosed with Pulmonary Fibrosis in 2022 and by July of that year, she was placed on the double lung transplant list.

She fought valiantly during her battle with this illness, never losing her sense of humour, love for others, and appreciation for life.

Unfortunately, she wasn't strong enough to continue and passed away on 21 March 2025.

Those fortunate enough to know Mum recognise that she was the most special lady in the world; words can hardly convey the profound impact she had on so many of us. APF holds immense significance for us, and we wish to express our gratitude for the support we received throughout Mum's journey."

Our fundraising achievements and supporters

Transformative grant funding

We extend our deepest gratitude to all our grant funders, whose unwavering support has been instrumental in helping us grow. Their generous contributions have provided the essential resources needed to expand our reach, enhance our services and continue making a meaningful difference to the people we support. Special thanks to: Christos Lazari Foundation, Miss Hansons Charitable Trust, The Hospital Saturday Fund, The National Lottery Community Fund and The Noble Charitable Trust.

Partnerships in action

Through strategic collaborations with corporate partners and the pharmaceutical industry, we have significantly boosted our fundraising efforts this year. These partnerships have not only provided essential financial support but also our ability to deliver on key projects and initiatives. By aligning our mission with the goals of these partners, it strengthens our capacity to make a meaningful impact. Together, we've made great strides in advancing our cause, and we are deeply grateful for the continued commitment and generosity. Our sincere thanks go to: AIS, Avalyn, Boehringer Ingelheim, Bristol Myers Squibb, Ciconi, Endeavor, Equilaw, Irwin Mitchell, Kennett Leasing and Trevi Therapeutics.

Ambitious plans for the future

We have set bold and ambitious goals for the next five years, aiming to significantly increase our income to expand both our support services and research portfolio. Our vision is clear: A future where everyone with pulmonary fibrosis has access to effective, evidence-based care and ultimately, a cure. This expansion will allow us to provide more comprehensive support to patients and their families, fund groundbreaking research, and advance innovative treatments.

However, achieving these aspirations, relies on the continued generosity and commitment of our donors, fundraisers, corporate partners and trusts and foundations. Every contribution, no matter how big or small, plays a vital role in helping us achieve our mission and brings us one step closer to a world where no one has to navigate pulmonary fibrosis alone.

Your support not only transforms lives today but also creates a brighter future for all people affected by pulmonary fibrosis. We are deeply grateful for your unwavering commitment to our cause. Thank you for standing with us every step of the way, together we are stronger.

Looking ahead

The next five years represent a pivotal window for progress on pulmonary fibrosis care and research. Despite its severity, pulmonary fibrosis remains under-recognised and underfunded. The number of people affected is growing, NHS services are overstretched and research breakthroughs are urgently needed.

Our new 2025–2030 strategy is built around three bold priorities, each designed to drive meaningful change for people affected by pulmonary fibrosis.

These priorities respond to the opportunities we see and the urgent challenges we must confront. Each strategic priority sets out a major focus area where APF will concentrate energy, investment and leadership over the next five years.

Our three strategic priorities

For Every Breath

Expanding trusted support, information and services so that no one faces pulmonary fibrosis alone.

For Every Journey

Championing faster diagnosis, fairer care and a world-leading model of pulmonary fibrosis healthcare.

For Every Future

Investing in bold, inclusive research and discovery that improves lives now and brings us closer to a cure.

These priorities reflect who we are, a charity rooted in compassion, driven by lived experience and determined to create lasting change.

Every project and partnership we pursue through this strategy is aligned to these priorities.

Together, they form the engine of progress that will define the next chapter for Action for Pulmonary Fibrosis and, most importantly, for the thousands of families we serve.

Structure, governance and management

Governance overview

Action for Pulmonary Fibrosis (APF) was established as a Charitable Incorporated Organisation (CIO) in June 2013, registered with the Charity Commission for England and Wales. Its governing document, the Constitution, was approved by the trustees on 28 May 2013. On 25 May 2021, Action for Pulmonary Fibrosis also achieved registration with the Office of the Scottish Charity Regulator (OSCR).

Almost all trustees bring direct experience of pulmonary fibrosis, whether through personal or family connections or as medical professionals, ensuring the charity's work is informed by lived experiences and healthcare expertise.

Board of Trustees

The Board of Trustees meets quarterly to oversee the charity's progress, establish policy and strategy and ensure compliance with charity regulations. At the start of each financial year, the trustees approve an annual plan and budget. During each meeting, progress reports are reviewed, significant risks are assessed and the effectiveness of internal controls is monitored.

The Board also engages professional advisers as needed to provide legal and financial guidance.

Recruitment and appointment of trustees

To respond to evolving challenges and ensure a broad mix of expertise, the Board regularly reviews its structure and actively recruits new trustees when needed. Many of our trustees have a personal connection to pulmonary fibrosis and bring valuable skills and experience to help the charity thrive.

Trustee vacancies are publicly advertised and candidates take part in a structured selection process. This includes submitting a formal application and attending an interview with current trustees. Shortlisted applicants are then invited to observe a Board meeting before a final decision is made by the trustees.

Once appointed, new trustees complete an induction programme to help them understand the charity's mission, operations and their governance responsibilities as part of the Board.

Organisational structure

The Chief Executive Officer (CEO) works in close partnership with the senior leadership team to steer the charity, ensuring its work remains aligned with its strategic objectives. Together, they provide strong, effective leadership and foster a culture of collaboration, innovation and shared purpose across the organisation.

The foundation of APF's governance is the Finance and Risk Committee, which plays a crucial role in overseeing the charity's financial health and operational integrity. The committee ensures that budgets are well-managed, risks are effectively mitigated and policies are regularly reviewed to maintain high standards. It is also responsible for overseeing staff remuneration, ensuring fairness and alignment with the charity's values.

The committee comprises the CEO, Director of Finance and Operations, Director of Fundraising and Communications, Treasurer, and at least two trustees. It meets quarterly, ahead of Board meetings, to support informed, transparent and accountable decision-making.

In addition to this, the Board establishes sub-committees as needed to focus on specific initiatives or areas of work. These flexible working groups allow APF to respond swiftly and effectively to emerging priorities, helping the organisation remain agile and forward-thinking.

The Board of Trustees has approved a new staff pay framework policy as of December 2025. The framework adopts the NCVO job-level framework for role evaluation and pay benchmarking, with slight amendments to fit the needs of APF. The framework embeds compliance with the living wage foundation to ensure equality and transparency standards and supports recruitment, retention and motivation of staff through equitable and sustainable remuneration.

APF is proud to be registered with the Fundraising Regulator, demonstrating its commitment to ethical and transparent fundraising. This accreditation reinforces the charity's dedication to building trust with supporters and delivering meaningful, high-quality support to those affected by pulmonary fibrosis. APF did not receive any fundraising complaints during 2024-2025.

Related Party Transactions

Stephen Jones and Helen Parfrey, trustees of Action for Pulmonary Fibrosis (APF) and also board members of the European Idiopathic Pulmonary Fibrosis and related disorders Federation (EU-IPFF). During the year, APF received income of £3,989 from EU-IPFF for speaker fees (2023/24: £2,628 for speaker fees). No amounts were outstanding to APF at the year end.

APF received an aggregate value of £400 from one Trustee, with no conditions attached.

The trustees are not aware of any other related party transactions during the period.

Public benefit statement

The charity trustees have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission, in exercising their powers or duties. Charity activities and the support provided are available to all those affected by pulmonary fibrosis.

Financial review 24/25

We are pleased to report that Action for Pulmonary Fibrosis (APF) has increased its financial position, with a surplus of **£207,302** at the end of the financial year (2023/24: Deficit £706,798). Income for the year was **£1,991,368** (2023/24: £1,485,083). This increase was driven by an inspiring rise in legacy income, highlighted by an incredibly generous gift from a legator. We also saw strong growth across community and challenge events, as well as significant income raised through in-memory and individual giving, reflecting the wonderful commitment and support of our donors.

A restricted funds balance of **£114,008** reflects where donors have formally specified that their gifts are used for a particular purpose. This value includes grants for specific projects and appeals or campaign income where a project has been pre-defined.

The total value of unrestricted funds amounts to: **£898,990** which are funds that have been gifted to APF with no formal restriction, of which: **£359,430** have been designated out of the unrestricted funds by the Board of Trustees for specific purposes. These funds will be used in accordance with the fund descriptions and in line with donor wishes.

A free reserve balance of **£539,560** of unrestricted, undesignated funds that are not currently committed to a project and can be utilised as the Board of Trustees sees fit.

Our total expenditure for the year was **£1,784,066** (2023/24: £2,191,881). The previous year's figure included the award of £599,671 for two new three-year research fellowships.

Further details are provided in the attached accounts, but our overall financial health remains favourable. We look forward to building on this strong foundation in the coming year as we work toward our mission of supporting everyone affected by pulmonary fibrosis (PF).

Financial review 24/25

Statement on reserves

A new reserve policy was approved by the Board of Trustees in February 2025, which defines the charity's approach to holding reserves.

The Board of Trustees considers it prudent to maintain a level of free reserves that provides the charity with sufficient working capital to support its core fundraising, support and governance activities for a period of 3 months (£350,000), plus an additional £150,000 to meet any unexpected call on funds or opportunities that may present themselves at short notice.

Having carefully considered the best interests of the charity and its beneficiaries, the Board of Trustees believes it appropriate to aim to hold a total of £500,000 free reserves. This approach enables the charity to respond effectively to both new opportunities and unforeseen challenges, allowing time for a measured response and the creation of appropriate plans, rather than relying on emergency measures.

If free reserves drop below this threshold, the Board of Trustees will determine whether the shortfall is due to temporary circumstances, or if immediate corrective action is required.

As of 31 June 2025, the charity held free reserves totalling **£539,560** (2023/24: £328,257), exceeding the set reserve policy position.

APF is committed to advancing research and provides conference awards, small research grants and fellowship funding (every three years) through its grant giving function. In order to ensure that there is not a shortfall in the funds available as the grant giving needs arise, APF has designated some of its income to a total balance at year end of £359,430 towards research projects to provide financial stability for the future commitments.

APF may designate its income for the projects and programs that have been outlined in the new five-year strategy and as part of the financial planning for the future to deliver its objectives.

Risk management

The Board of Trustees have overall responsibility for ensuring there are effective risk management and internal control systems in place to manage the operational and strategic risks which APF may face. APF maintains a comprehensive risk register with regular review by the Senior Leadership Team, Finance and Risk Committee and the Board of Trustees that aims to reduce risks to their lowest possible level. Each risk has an assigned risk 'owner' from the Senior Leadership Team who is responsible for managing local risks alongside a 'handler' to work proactively to reduce the risk in between reviews. Emerging risks are assessed and added to the risk register as the occur and if necessary, a task and finish group assembled to proactively monitor and respond to an incident as required.

These risks have been grouped into principal categories for the purpose of the annual report:

1. Financial Resilience
2. Governance, Reporting & Board Decision-Making
3. Achieving Objectives
4. Regulatory Compliance
5. People
6. Data, Security, Systems & Internal Controls
7. Stakeholder Influence & Partnerships

These principal risk areas are not an indication of likelihood or specific concern but highlight the areas that the board have chosen to monitor to ensure that the charity is managed effectively.

The table on the following three pages highlights those principal risk areas and a summary of the mitigations in place:

Risk management

Principal risk area
Financial Resilience
Summary of risks
Economic uncertainty, high inflation, and a competitive fundraising environment may affect APF's income and financial stability. Dependence on specific income streams, as well as changes in government policy, tax regimes or funder priorities, could reduce funding and limit the charity's ability to deliver its strategy. Competition from other pulmonary fibrosis charities may also reduce profile and income, thereby impacting services for beneficiaries.
Mitigation
Financial performance is closely monitored by SLT and reviewed by the Finance & Risk Committee. Budgeting, forecasting and reporting have been strengthened, improving visibility of restricted income, dependencies and financial risk. Reserves are monitored against policy targets, and business cases are required for all new projects. APF continues to diversify income across individual giving, corporate partners, trusts and pharma to reduce dependency. A structured supporter journey, stewardship of major donors, and planned engagement with pharma partners support long-term growth and resilience.

Principal risk area
Governance, Reporting & Board Decision-Making
Summary of risks
Gaps in trustee skills, commitment, representation or diversity could weaken governance, strategic oversight and decision-making. Unmanaged conflicts of interest or insufficient strategic planning may undermine independence, credibility and organisational direction. Key strategic documents falling out of date or not being updated in line with legislation.
Mitigation
Mitigations include regular trustee skills analysis to inform recruitment and development. A skills audit for the Trustees will take place in 25/26 and as Trustee positions become available the charity will proactively recruit those that represent our community. Conflicts of interest are managed through declarations, registers, standing agenda items, and due diligence. This policy will be strengthened in 25/26. A document control system will be implemented to track all policies. All approved policies will be uploaded to the system for monitoring and compliance purposes. Accountability is demonstrated through the document owner who is responsible for updating necessary documents when there are legislative or other relevant changes.

Risk management

Principal risk area
Achieving Objectives
Summary of risks
Without clear strategic prioritisation and decision-making processes, the charity may struggle to deliver its objectives effectively.
Mitigation
Strategic delivery is supported through the approved strategy, SLT operational plans. In 2025/6 the charity will introduce clearer objectives and policies to support consistent decision making.

Principal risk area
Regulatory Compliance
Summary of risks
Failure to comply with fundraising regulations, donor restrictions, or statutory reporting requirements could lead to regulatory action, reputational damage and loss of funding.
Mitigation
APF adheres to the Fundraising Regulator Code, maintains ethical fundraising exclusions, and conducts enhanced due diligence for partners. The charity is preparing for the change in code (Nov 2025) Donor restrictions are supported by an improved income-coding structure, strengthened gift processing and month-end checks.

Principal risk area
People
Summary of risks
APF’s ability to deliver its strategy relies on attracting, developing and retaining skilled and motivated staff and volunteers. Poor retention, lack of support or the emotional impact of the work could reduce capacity, impact wellbeing and disrupt service continuity. The nature of our work can take an emotional and physical toll, risks include our ability to effectively protect and support our staff and volunteers.
Mitigation
The Staff Handbook and HR processes have been updated, including structured reviews, flexible working, safeguarding guidance and learning & development pathways. Vero supports compliant recruitment, DBS checks, performance management and HR advice. Staff morale is monitored through an annual staff survey and regular communication updates help keep staff, volunteers informed. Retention is supported through training, supervision, pay review, exit interviews and quarterly reporting to the FRC. Health & Safety, safeguarding and lone-working risks are managed through policies, risk assessments, mandatory training, check-ins and safe travel arrangements.

Risk management

Principal risk area
Data, Security, Systems & Internal Controls
Summary of risks
Failure to protect and effectively use data could reduce APF’s reach and impact, limit income generation and cause significant reputational harm should data be lost or misused. Weak internal controls and segregation of duties could lead to error and fraud risks.
Mitigation
Information governance has been strengthened through controlled SharePoint access, retention planning, and Multi Factor Authentication. Regulatory and data compliance is supported through updated Data Protection Policies, nominated Data Protection Officer, mandatory training and cyber insurance. External audits, policy updates and keeping abreast of regulatory and legislative updates help to protect the integrity and security of our data. Fraud and error risks are mitigated through approval hierarchies, restricted banking access, supplier verification and strengthened banking arrangements.

Principal risk area
Stakeholder Influence & Partnerships
Summary of risks
Adverse events or misaligned partnerships may damage APF’s reputation and affect income or our ability to achieve our charitable objectives Risks include deterioration in relationships with major funders, leading to reduced funding, reduced support, and fewer resources available to deliver charitable activities and services. Research funding decisions that are not aligned with AMRC best practice and APF strategy.
Mitigation
External risks are managed through comprehensive risk management reporting. Reputation is protected through pro-active communications and stakeholder engagement, brand guidelines, ABPI awareness, and transparency around pharma relationships and lobbying. Research funding is controlled through budgeting, peer review and panel processes aligned to AMRC guidance and APF priorities.

Statement of trustee responsibilities

For the year ended 30 June 2025

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales, and in Scotland, requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charity and the incoming resources and application of resources, including the net income or expenditure, of the charity for the year.

In preparing those financial statements the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts(Scotland) Regulations 2006 (as amended) and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and the integrity of the corporate and financial information included in the charity's website. Legislation in the United Kingdom governing the preparation of the financial statements may differ from legislation in other jurisdictions. The trustees are members of the charity, but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Approved by the trustees on 9 April 2026
and signed on their behalf by

Mike Stubbins – Chair

Reference and administrative details

2024-25 Trustees	Notes
Dr. Mike Stubbins	Chair of the Board of Trustees
Wendy Dickinson	
Dr. Rebecca Lang	Stepped down on 13th September 2025
Stephen Morgan-Hyland	
Stephen Jones	Stepped down on 13th September 2025
Dr. Simon Hart	
Dr. Helen Parfrey	
Matt Suddart	
Matthew Kemp	
Emma Goodes	Joined APF on 9th November 2024

We extend our warmest thanks to all our Trustees for their service and dedication to Action for Pulmonary Fibrosis (APF). For those that have stepped down, we wish them every success for the future and remain deeply grateful for their contribution and guidance.

The Trustees volunteer their skills, experience and time to provide the leadership and guidance to further APF's mission. Their unwavering commitment and contributions have helped shape APF's work and will continue to improve the lives of people affected by pulmonary fibrosis (PF).

In keeping with the charity's ethos of being patient led, at least 70% of our trustees have been personally affected by pulmonary fibrosis either as a patient or family member. Our trustees also include medical professionals who are leaders in pulmonary fibrosis care and research.

Chief Executive Officer:
Daniel Saxton

Registered Charity Number:
1152399 (England & Wales)
SC050992 (Scotland)

Registered Office:
Stuart House, East Wing, St John's Street,
Peterborough, PE1 5DD

Bankers:
CAF Bank Limited, 25 Kings Hill Avenue,
Kings Hill, West Malling, Kent, ME19 4JQ

Auditors:
Godfrey Wilson Limited
(Chartered accountants and statutory auditors)
5th Floor Mariner House, 62 Prince Street,
Bristol, BS1 4QD

Lawyers:
Bevan Brittan
45 Church Street, Birmingham, B3 2RT

Independent auditor’s report

To the trustees of Action for Pulmonary Fibrosis

Opinion

We have audited the financial statements of Action for Pulmonary Fibrosis (the ‘charity’) for the year ended 30 June 2025 which comprise the statement of financial activities, balance sheet, statement of cash flows and the related notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charity’s affairs as at 30 June 2025 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011 and the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and the provisions available for small entities, in the circumstances set out in note 10 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Independent auditor’s report

Matters on which we are required to report by exception
We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the trustees’ report is inconsistent in any material respect with the financial statements; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of the trustees
As explained more fully in the trustees’ responsibilities statement set out in the trustees’ report, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The procedures we carried out and the extent to which they are capable of detecting irregularities, including fraud, are detailed below:

(1) We obtained an understanding of the legal and regulatory framework that the charity operates in, and assessed the risk of non-compliance with applicable laws and regulations. Throughout the audit, we remained alert to possible indications of non-compliance.

(2) We reviewed the charity’s policies and procedures in relation to:

- Identifying, evaluating and complying with laws and regulations, and whether they were aware of any instances of non-compliance;
- Detecting and responding to the risk of fraud, and whether they were aware of any actual, suspected or alleged fraud; and
- Designing and implementing internal controls to mitigate the risk of non-compliance with laws and regulations, including fraud.

(3) We inspected the minutes of trustee meetings.

Independent auditor’s report

(4) We enquired about any non-routine communication with regulators and reviewed any reports made to them.

(5) We reviewed the financial statement disclosures and assessed their compliance with applicable laws and regulations.

(6) We performed analytical procedures to identify any unusual or unexpected transactions or balances that may indicate a risk of material fraud or error.

(7) We assessed the risk of fraud through management override of controls and carried out procedures to address this risk. Our procedures included:

- Testing the appropriateness of journal entries;
- Assessing judgements and accounting estimates for potential bias;
- Reviewing related party transactions; and
- Testing transactions that are unusual or outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. Irregularities that arise due to fraud can be even harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charity ' s trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008 and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity ' s trustees those matters we are required to state to them in an auditor ' s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity ' s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Godfrey Wilson Limited

Date: 13 April 2026

GODFREY WILSON LIMITED
Chartered accountants and statutory auditors
5th Floor Mariner House
62 Prince Street
Bristol
BS1 4QD

Godfrey Wilson Limited is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

Statement of financial activities

For the year ended 30 June 2025

	Note	Restricted £	Unrestricted £	**2025 Total £**	2024 Total £
Income from:					
Donations and legacies	3	25,419	1,602,916	**1,628,335**	1,077,952
Charitable activities	4	262,703	83,080	**345,783**	381,138
Investments		-	17,130	**17,130**	25,043
Other trading income	5	-	120	**120**	950
Total income		288,122	1,703,246	**1,991,368**	1,485,083
Expenditure on:					
Raising funds		-	431,621	**431,621**	388,202
Charitable activities		292,123	1,060,322	**1,352,445**	1,803,679
Total expenditure	7	292,123	1,491,943	**1,784,066**	2,191,881
Net (expenditure) / income		(4,001)	211,303	**207,302**	(706,798)
Transfers between funds	19	(8,500)	8,500	**-**	-
Net movement in funds	10	(12,501)	219,803	**207,302**	(706,798)
Reconciliation of funds:					
Total funds brought forward		126,509	679,187	**805,696**	1,512,494
Total funds carried forward		114,008	898,990	**1,012,998**	805,696

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 19 to the accounts.

Balance sheet

As at 30 June 2025

			2025	2024
	Note	**£**	**£**	£
Fixed assets				
Tangible assets	13		**7,984**	10,448
Current assets				
Debtors	14	**105,459**		97,741
Current asset investments		**928,420**		1,251,369
Cash at bank and in hand		**615,387**		122,075
		1,649,266		1,471,185
Liabilities				
Creditors: amounts falling due within 1 year	15	**(288,795)**		(260,139)
Net current assets			**1,360,471**	1,211,046
Total assets less current liabilities			**1,368,455**	1,221,494
Creditors: amounts falling due after more than 1 year	16		**(355,457)**	(415,798)
Net assets	18		**1,012,998**	805,696
Funds	19			
Restricted funds			**114,008**	126,509
Unrestricted funds				
Designated funds			**359,430**	350,930
General funds			**539,560**	328,257
Total charity funds			**1,012,998**	805,696

Approved by the trustees on 9 April 2026 and signed on their behalf by

Michael Stubbins - Chair

Statement of cash flow

For the year ended 30 June 2025

	2025 **£**	2024 £
Cash provided by operating activities:		
Net movement in funds	**207,302**	(706,798)
Adjustments for:		
Investment income	**(17,130)**	(25,043)
Increase in debtors	**(7,718)**	(35,440)
(Decrease) / increase in creditors	**(31,685)**	471,709
Depreciation	**7,037**	4,457
Loss on disposal of fixed assets	**1,756**	-
Net cash provided by / (used in) operating activities	**159,562**	(291,115)
Cash flows from investing activities:		
Investment income	**17,130**	25,043
Purchase of tangible fixed assets	**(6,329)**	(5,111)
Net cash provided by investing activities	**10,801**	19,932
Increase / (decrease) in cash and cash equivalents in the year	**170,363**	(271,183)
Cash and cash equivalents at the beginning of the year	**1,373,444**	1,644,627
Cash and cash equivalents at the end of the year	**1,543,807**	1,373,444

Analysis of cash and cash equivalents

Current asset investments	**928,420**	1,251,369
Cash at bank and in hand	**615,387**	122,075
Cash and cash equivalents at the end of the year	**1,543,807**	1,373,444

The charity has not provided an analysis of changes in net debt as it does not have any long term financing arrangements.

Notes to the financial statements

For the year ended 30 June 2025

1. Accounting policies

a) General information and basis of preparation

Action for Pulmonary Fibrosis is a charitable incorporated organisation registered in Scotland, England and Wales. The registered office address is Stuart House, East Wing, St John's Street, Peterborough, PE1 5DD.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities in preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Action for Pulmonary Fibrosis meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

b) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern, which the trustees consider appropriate having regard to the current level of unrestricted reserves. There are no material uncertainties about the charity's ability to continue as a going concern.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from the government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Notes to the financial statements

For the year ended 30 June 2025

---

1. Accounting policies (continued)

e) Funds accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Grants payable

Grants payable are charged in the year in which the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached have been fulfilled. Grants offered subject to conditions at the year end are noted as commitment but are not accrued as expenditure.

h) Allocation of support and governance costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Governance costs are the costs associated with the governance arrangements of the charity, including the costs of complying with constitutional and statutory requirements and any costs associated with the strategic management of the charity’s activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the basis of staff time spent on each of these area. The percentages used were as follows:

	2025	2024
Raising funds	**21%**	23%
Charitable activities	**79%**	77%

i) Tangible fixed assets

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Computer equipment	3 years

Items of equipment are capitalised where the purchase price exceeds £1,000.

j) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1. Accounting policies (continued)

k) Current asset investments

Current asset investments consists of short term cash deposits with a maturity date of less than one year from the balance sheet date held for investment purposes rather than to meet short term cash commitments as they fall due.

l) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m) Creditors

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

n) Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently recognised at amortised cost using the effective interest method.

o) Pension costs

The charity operates a defined contribution pension scheme for its employees. There are no further liabilities other than that already recognised in the SOFA.

p) Operating leases

Operating lease payments are recognised as an expense on a straight-line basis over the lease term.

q) Accounting estimates and key judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

There are no key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements.

2. Prior period comparatives: statement of financial activities

	Restricted £	Unrestricted £	2024 Total £
Income from:			
Donations and legacies	17,147	1,060,805	1,077,952
Charitable activities	306,617	74,521	381,138
Investments	-	25,043	25,043
Other trading activities	-	950	950
Total income	323,764	1,161,319	1,485,083
Expenditure on:			
Raising funds	-	388,202	388,202
Charitable activities	241,275	1,562,404	1,803,679
Total expenditure	241,275	1,950,606	2,191,881
Net income / expenditure	82,489	(789,287)	(706,798)
Transfers between funds	-	-	-
Net movement in funds	82,489	(789,287)	(706,798)

3. Income from donations and legacies

	Restricted £	Unrestricted £	**2025 Total £**
Legacies	-	447,984	**447,984**
Donations from individuals and fundraising	25,419	1,154,932	**1,180,351**
Total income from donations and legacies	25,419	1,602,916	**1,628,335**

Prior period comparative

	Restricted £	Unrestricted £	2024 Total £
Legacies	-	25,687	25,687
Donations from individuals and fundraising	17,147	1,035,118	1,052,265
Total income from donations and legacies	17,147	1,060,805	1,077,952

Notes to the financial statements

For the year ended 30 June 2025

4. Income from charitable activities

	Restricted £	Unrestricted £	**2025** **Total** **£**
Corporate grants	32,000	15,520	**47,520**
Trusts and foundations	230,703	36,257	**266,960**
Speaker and consultancy fees	-	31,303	**31,303**
Total income from charitable activities	262,703	83,080	**345,783**

Prior period comparative

	Restricted £	Unrestricted £	2024 Total £
Corporate grants	98,500	17,767	116,267
Trusts and foundations	208,117	54,126	262,243
Speaker and consultancy fees	-	2,628	2,628
Total income from charitable activities	306,617	74,521	381,138

5. Income from other trading activities

	2025 **£**	2024 £
Merchandise sales	**120**	950
Total income from other trading activities	**120**	950

All income from other trading activities was unrestricted in the current and prior years.

6. Government grants

The charity received a government grant, defined as funding from the National Lottery Community Fund, to fund support services. The total value of such grants for the year ending 30 June 2025 was £167,000 (2024: £168,118). There were no unfulfilled conditions or contingencies attached to these grants in 2024/25.

7. Total expenditure

	Raising funds £	Charitable activities £	Support and governance costs £	**2025 Total £**
Staff costs (note 11)	228,739	874,088	120,918	**1,223,745**
Freelance costs (note 11)	62,604	54,825	33,120	**150,549**
Travel and subsistence	-	-	38,044	**38,044**
Grants payable (note 8)	-	37,780	-	**37,780**
Patient surveys	-	2,660	1,716	**4,376**
Fundraising costs	59,296	-	-	**59,296**
Marketing and communications	299	74,779	-	**75,078**
Premises costs	-	-	49,270	**49,270**
Admin costs	-	-	87,847	**87,847**
Other staffing costs	-	-	26,908	**26,908**
Governance costs	-	-	24,136	**24,136**
Depreciation	-	-	7,037	**7,037**
Sub-total	350,938	1,044,132	388,996	**1,784,066**
Allocation of support and governance costs	80,683	308,313	(388,996)	-
Total expenditure	**431,621**	**1,352,445**	**-**	**1,784,066**

Prior year comparative:

	Raising funds £	Charitable activities £	Support and governance costs £	2024 Total £
Staff costs (note 11)	231,311	763,210	90,254	1,084,775
Freelance costs (note 11)	8,225	43,860	62,330	114,415
Travel and subsistence	-	-	41,252	41,252
Grants payable (note 8)	-	614,625	-	614,625
Training costs	-	-	396	396
Patient surveys	-	192	-	192
Fundraising costs	55,200	-	-	55,200
Marketing and communications	658	75,569	300	76,527
Premises costs	-	-	49,606	49,606
Admin costs	-	-	105,515	105,515
Other staffing costs	-	-	34,271	34,271
Governance costs	-	-	10,650	10,650
Depreciation	-	-	4,457	4,457
Sub-total	295,394	1,497,456	399,031	2,191,881
Allocation of support and governance costs	92,808	306,223	(399,031)	-
Total expenditure	388,202	1,803,679	-	2,191,881

Notes to the financial statements

For the year ended 30 June 2025

8. Grants payable

During the year, 15 (2024: 8) new grants were awarded to 15 institutions (2024: 7) to fund research fellowships and support sessions and 10 to individuals (2024: 9) for travel to research events. Total grants committed to during the year were as follows:

	2025 **£**	2024 £
Grants payable to institutions:		
Fellowships		
University of Cambridge	**-**	299,998
Imperial College London	**-**	299,673
Research awards		
British Association of Lung Research	**4,500**	4,500
University of Birmingham	**9,876**	-
Imperial College London	**9,829**	2,500
Support groups		
Portsmouth Support Group	**500**	-
Newcastle Support Group	**500**	-
Rhondda Cynon Taf Support Group	**500**	-
Worthing Support Group	**500**	-
Bradford Support Group	**500**	-
Isle of Wight Support Group	**135**	-
Epsom and St Helier Support Group	**500**	-
West Wiltshire Support Group	**500**	-
West Cornwall Support Group	**500**	-
Leicester South Asian Support Group	**500**	-
Crawley Support Group	**240**	-
Blackpool Support Group	**500**	-
Huddersfield Support Group	**-**	600
Tunbridge Wells and Maidstone Support Group	**-**	350
Torquay Support Group	**-**	500
Ayrshire Support Group	**-**	500
Total grants payable to institutions	**29,580**	608,621
Grants payable to individuals	**8,200**	6,004
Total grants committed during the period	**37,780**	614,625

9. Grants commitments

	2025 **£**	2024 £
Grant commitments brought forward	**579,636**	56,931
Grants committed during the period (note 8)	**37,780**	614,625
Grants paid during the period	**(85,822)**	(91,920)
Grant commitments carried forward	**531,594**	579,636

10. Net movement in funds

This is stated after charging:

	2025 **£**	2024 £
Depreciation	**7,037**	4,457
Operating lease payments	**29,595**	20,079
Trustees' remuneration	**Nil**	Nil
Trustees' reimbursed expenses	**Nil**	337
Auditors' remuneration:		
▪ Statutory audit (excluding VAT)	**7,000**	5,775

During the year, no trustees received reimbursed expenses (2024: 2 trustees were reimbursed £337 for travel expenses). All expenses incurred were in the course of the organisation's charitable activities.

In common with other charities of our size and nature we use our auditors to assist with the preparation of the financial statements.

11. Staff costs and numbers

Staff costs were as follows:

	2025 **£**	2024 £
Salaries and wages	**1,097,240**	958,898
Social security costs	**103,949**	88,882
Pension costs	**22,556**	36,995
Freelance staff	**150,549**	114,415
	1,374,294	1,199,190

One employee earned between £70,000 and £80,000 during the year (2024: one employee earned between £70,000 and £80,000).

The key management personnel of the charity comprise the trustees and senior leadership team (2023: the trustees and the Chief Executive). The total employee benefits of the key management personnel were £349,446 (2024: £344,633).

Notes to the financial statements

For the year ended 30 June 2025

11. Staff costs and numbers (continued)

Included in salaries and wages are redundancy and termination costs totalling £18,648 (2024: £2,000). Redundancy and termination costs have been funded from unrestricted general funds (note 19).

	2025 No.	2024 No.
Average head count	**34**	32

12. Taxation

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

13. Tangible fixed assets

	Computer equipment	**Total £**
Cost		
At 1 July 2024	16,538	**16,538**
Additions in year	6,329	**6,329**
Disposals	(1,756)	**(1,756)**
At 30 June 2025	21,111	**21,111**
Depreciation		
At 1 July 2024	6,090	**6,090**
Charge for the year	7,037	**7,037**
At 30 June 2025	13,127	**13,127**
Net book value		
At 30 June 2025	**7,984**	**7,984**
At 30 June 2024	10,448	10,448

14. Debtors

	2025 £	2024 £
Trade debtors	**16,205**	55,806
Accrued income	**76,092**	30,037
Prepayments	**13,162**	11,898
	105,459	97,741

Notes to the financial statements

For the year ended 30 June 2025

15. Creditors: amounts due within 1 year

	2025	2024
	£	£
Trade creditors	**48,404**	70,913
Accruals	**38,759**	6,930
Grant commitments (note 9)	**176,137**	163,838
Social security	**19,720**	18,458
Other creditors	**5,775**	-
	288,795	260,139

16. Creditors: amounts due after 1 year

	2025	2024
	£	£
Grant commitments (note 9)	**355,457**	415,798

17. Contingent assets

Action for Pulmonary Fibrosis were notified of a number of legacies during the year ended 30 June 2025, for which the amount receivable cannot be reliably estimated. These financial statements do not include any estimated future amounts receivable. Indications are that the value of these potential legacies is in the region of £60,000 - £70,000 (2024: £72,000).

18. Analysis of net assets between funds

	Restricted funds £	Designated funds £	General funds £	**Total funds £**
Fixed assets	-	-	7,984	**7,984**
Current assets	114,008	891,024	644,234	**1,649,266**
Current liabilities	-	(176,137)	(112,658)	**(288,795)**
Non-current liabilities	-	(355,457)	-	**(355,457)**
Net assets at 30 June 2025	**114,008**	**359,430**	**539,560**	**1,012,998**

Prior period comparative	Restricted funds £	Designated funds £	General funds £	Total funds £
Fixed assets	-	-	10,448	10,448
Current assets	126,604	330,895	1,013,686	1,471,185
Current liabilities	-	(163,838)	(96,301)	(260,139)
Non-current liabilities	-	(415,798)	-	(415,798)
Net assets at 30 June 2024	126,509	350,930	328,257	805,696

19. Movements in funds

	At 1 July 2024 £	Income £	Expenditure £	Transfers between funds £	**At 30 June 2025 £**
Restricted funds					
National Lottery Community Fund	-	167,000	(97,417)	-	**69,583**
Onevoice ILD	70,460	30,000	(56,035)	-	**44,425**
Research donations	-	42,394	(42,394)	-	**-**
Support donations	-	23,808	(23,808)	-	**-**
Location specific support services	-	14,420	(14,420)	-	**-**
Research Fellowships	-	8,500	-	(8,500)	**-**
Trevi Therapeutics	13,209	2,000	(15,209)	-	**-**
Garfield Weston	39,442	-	(39,442)	-	**-**
Northern Ireland donations	1,213	-	(1,213)	-	**-**
Wales donations	855	-	(855)	-	**-**
Hospital Saturday Fund	630	-	(630)	-	**-**
Scotland donations	528	-	(528)	-	**-**
D'Oyly Carte Charitable Trust	172	-	(172)	-	**-**
Total restricted funds	126,509	288,122	(292,123)	(8,500)	**114,008**
Unrestricted funds					
Designated funds					
Research fund	350,930	-	-	8,500	**359,430**
Total designated funds	350,930	-	-	8,500	**359,430**
General funds	328,257	1,703,246	(1,491,943)	-	**539,560**
Total unrestricted funds	679,187	1,703,246	(1,491,943)	8,500	**898,990**
Total funds	805,696	1,991,368	(1,784,066)	-	**1,012,998**

Purposes of restricted funds

National Lottery Community Fund	Funding for APF's support services.
Onevoice ILD	Funding for APF to act as a central voice to advocate for patients with a range of Intersitial Lung Diseases.
Research donations	These are donations received specifically for research.
Support donations	These are donations received specifically for support services.
Location specifc support donations	Funding for support services within specific regions have been aggregated for the statutory accounts.

19. Movements in funds (continued)

Purposes of restricted funds (continued)

Research Fellowships	Funding to contribute to APF's ongoing research fellowships.
Trevi Therapeutics	This fund is for support services in Scotland (including Support Group coordinator salary).
Garfield Weston	This fund is for support services growing volunteering, and is to be used towards volunteering salary costs, services admin and volunteer recruitment, training, expenses and marketing.
Northern Ireland donations	These donations for support services in Northern Ireland were received in the prior year.
Wales donations	These donations for support services in Wales were received in the prior year.
Hospital Saturday Fund	This fund is for support services.
Scotland donations	These donations for support services in Scotland were received in the prior year.
D'Oyly Carte Charitable Trust	This fund is to enable new and existing APF volunteers to receive training in order to better support patients and carers.

Purposes of designated funds

Research fund	A principal objective of Action for Pulmonary Fibrosis is to support and fund Research into the disease. Trustees have previously agreed to designate £951k for research to fund further research fellowships, with agreements totalling £599,671 awarded in the prior year. The balance carried forward is intended to be spent on future research fellowships.

Transfers between funds

Transfers between funds represent the contribution of restricted funds towards the research fellowship committed to in the prior year.

19. Movements in funds (continued)

Prior period comparative

	At 1 July 2023 £	Income £	Expenditure £	Transfers between funds £	At 30 June 2024 £
Restricted funds					
Onevoice ILD	-	90,000	(19,540)	-	70,460
Trevi Therapeutics	13,207	8,500	(8,498)	-	13,209
Hospital Saturday Fund	630	-	-	-	630
National Lottery Community Fund	10,919	168,118	(179,037)	-	-
D'Oyly Carte Charitable Trust	172	-	-	-	172
Garfield Weston	16,401	35,000	(11,959)	-	39,442
Northern Ireland donations	1,213	-	-	-	1,213
Research donations	-	17,146	(17,146)	-	-
Support donations	-	5,000	(5,000)	-	-
Scotland donations	623	-	(95)	-	528
Wales donations	855	-	-	-	855
Total restricted funds	44,020	323,764	(241,275)	-	126,509
Unrestricted funds					
Designated funds					
Research fund	950,601	-	(599,671)	-	350,930
Reserve fund	336,000	-	-	(336,000)	-
Total designated funds	1,286,601	-	(599,671)	(336,000)	350,930
General funds	181,873	1,161,319	(1,350,935)	336,000	328,257
Total unrestricted funds	1,468,474	1,161,319	(1,950,606)	-	679,187
Total funds	1,512,494	1,485,083	(2,191,881)	-	805,696

20. Operating leases

The charity had operating leases at the year end with total future minimum lease payments as follows:

	2025 £	2024 £
Amount falling due:		
Within 1 year	**5,361**	26,482
Within 1-5 years	**-**	1,306
	5,361	27,788

Notes to the financial statements

For the year ended 30 June 2025

---

21. Related party transactions

Stephen Jones and Helen Parfrey, trustees of Action for Pulmonary Fibrosis (APF), are also board members of European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF). During the year APF received income of £3,989 from EU-IPFF for speaker fees (2024: £2,628 for speaker fees). No amounts were outstanding to APF at the year end. Additionally, APF were invoied £254 for membership fees (2024: £nil), £254 was outstanding to EU-IPFF at the year end. In the year, the charity received £400 of unrestricted donations from trustees.

The trustees are not aware of any other related party transactions during the period.

Action for Pulmonary Fibrosis

General enquiries
01733 839642
info@actionpf.org

Contact our support team

✉ supportline@actionpf.org
☎ Support line: 01223 785725

Registered Office & Operational Address
Stuart House, East Wing, St John’s Street, Peterborough PE1 5DD

actionpf.org

Charity Commission England & Wales Registered Charity Number: 1152399
Scottish Charity Regulator Number: SC050992